Greg Mattingly
Midwest Research Group, St. Charles, MO, USA

Dr. Mattingly is a physician and principal investigator in clinical trials for Midwest Research Group. He is also a founding partner of St. Charles Psychiatric Associates where he treats children, adolescents and adults. A St Louis native, he earned his medical degree and received a Fulbright scholarship while attending Washington University. Dr. Mattingly is board certified in adult and adolescent psychiatry and is a Diplomat of the National Board of Medical Examiners. He is an Associate Clinical Professor at Washington University where he teaches psychopharmacology courses for the 3rd year medical students. Dr. Mattingly has been a principal investigator in over 400 clinical trials focusing on ADHD, anxiety disorders, major depression, bipolar disorder and schizophrenia. Having served on numerous national and international advisory panels, Dr. Mattingly has received awards and distinctions for clinical leadership and neuroscience research. Dr. Mattingly currently serves on the board of directors for APSARD-The American Professional Society of ADHD and Related Disorders and is a certified evaluator for the NFL regarding ADHD and head concussions. He also serves on the board of Headway House, a community support program for individuals with chronic mental illness. An avid runner and outdoorsman, Dr. Mattingly believes mind, body and spirit are important qualities for him and his family.



Advanced Psychopharmacology Preconference: 2024 as a Watershed Moment in Advanced Psychopharmacology - Four Cutting Edge, Emerging Therapies

Tuesday, October 29, 2024
9:00 AM - 12:00 PM

Exploring On-Label, Off-Label, and Real-World Strategies in the Treatment of Major Depressive Disorder

Tuesday, October 29, 2024
3:15 PM - 4:30 PM

An Evidence-based Roadmap to the Initial Management of ADHD

Wednesday, October 30, 2024
9:00 AM - 10:15 AM

Emotional Spectrum: Differentiating Between Sadness, Depression, and Bipolar Disorder

Wednesday, October 30, 2024
3:00 PM - 4:15 PM

Long-Acting Injectables Anti-psychotics: When LAIs Are the Best Choice for Schizophrenia Treatment

Wednesday, October 30, 2024
4:30 PM - 5:45 PM

ADHD in Adult Women: Challenges and New Directions

Thursday, October 31, 2024
3:45 PM - 5:00 PM

Addressing the Stimulant Crisis in America

Friday, November 01, 2024
9:00 AM - 10:15 AM

Psych Congress 2024: Final Thoughts and Panel Discussion

Saturday, November 02, 2024
4:15 PM - 4:30 PM